

May 28, 2013



Pressure BioSciences, Inc. to Present at the Marcum MicroCap Conference

SOUTH EASTON, Mass., May 28, 2013 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the 2nd Annual Marcum MicroCap Conference on Thursday, May 30th, at 4:00 pm EDT. The Conference is being held at the Grand Hyatt Hotel in New York City.

Mr. Schumacher's presentation will be webcast and may be viewed live at the following link (<http://wsj.com/webcast/marcum/pbio>) and up to 90 days thereafter on the Company's website (www.pressurebiosciences.com).

About Marcum LLP and the Marcum MicroCap Conference

The Marcum Microcap Conference will allow institutional investors, sell-side analysts, and investment bankers the opportunity to consider the investment prospect being showcased by the next generation of up-and-coming microcap companies in seven industries, including the Life Sciences. The Conference is expected to draw more than 1,000 attendees.

Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. Ranked among the top 15, Marcum LLP offers the resources of 1,100 professionals, including over 130 partners, in more than 20 offices throughout New York, New Jersey, Massachusetts, Connecticut, Pennsylvania, California, Florida, Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated \$6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

For more information about PBI and this press release, please click on the following website

link: <http://www.pressurebiosciences.com>

Investor Contacts:

Richard T. Schumacher, President and CEO, PBI (508) 230-1828 (T)

Conrad F. Mir, CFO, PBI (508) 230-1828 (T)

Timothy J. Connor, Managing Director, Benchmark Advisory (858) 568-7059 (T)

SOURCE Pressure BioSciences, Inc.